Opko Health Inc (OPK)

[Atlanta1]

Phillip Frost
I’ll close by just repeating that I personally am very, very satisfied with what we have going on now at OPKO. The products that we have on the market, 4Kscore to identify men at risk for developing prostate cancer or having prostate cancer; RAYALDEE a unique product to treat the stage three and four kidney disease patients who have low Vitamin D levels and secondary hypoparathyroidism.
These are both unique products and that’s what I really like. I really like. I like to be able to go out there with products that have their own story with limited competition. The pipeline I can only characterize as being outstanding. You can tell from my tone of voice that I’m very enthusiastic about the SARM, the molecule that we have with the Transition acquisition to treat benign prostatic hypertrophy. You can imagine with the constellation of properties of decreasing body fat, increasing muscle mass and bone strength, and at the same time lowering the PSA and decreasing the size of the prostate and therefore helping with the symptoms of BPH. You can imagine that’s a product whose appeal would be irresistible by physicians and patients who require it.
And I should tell you that in the United States alone, there are approximately 50 million men who suffer form BPH. So the market is, to say the least, quite large. The oxyntomodulin product, the dual-acting agonist for treating obesity and type II diabetes, that has the potential to be the best drug in its class to treat these conditions. We will know a little bit more after next trial, but what I said is absolutely true. It can be the best drug in its class.
And so far as BioReference is concerned, you heard that we are working on making it more efficient. It already is generating nice cash flow. We’re hoping that that will only increase. It’s helping with the marketing of the 4K product. And it wasn’t beyond that you can only imagine that we are very open to a new initiatives that will take that whole business to another level. We spent time considering such possibilities.


http://seekingalpha.com/article/4051267-opko-healths-opk-ceo-phillip-frost-q4-2016-results-earnings-call-transcript?page=7